Wanda Health, an intelligent platform for remote patient monitoring and virtual care, has successfully closed a new investment round and reported significant commercial progress in the United States. The funding package includes a £250,000 loan facility.
The company’s platform helps reduce hospitalisations and readmissions by collecting real-time data from patients in home and community settings, enabling clinicians to proactively identify and manage high-risk individuals.
Wanda has completed a further close of £834,000 through EIS investments, a debt facility, and CLA conversions. This brings the total raised in this round to £1.9m. The round was led by EMV Capital Partners Ltd, with the capital earmarked to support accelerated growth in response to rising commercial demand. The raise follows a period of strong and sustained commercial performance and further advances toward FDA approval of the platform.
The £250,000 loan facility is being deployed to support customer onboarding and growth as the business scales.
Earlier in the year, Wanda secured strategic partnerships with the COPD Foundation and the American Heart Association, strengthening its relationships with key clinical opinion leaders in its focus areas. The company has since expanded into several new market segments.
Wanda has now entered the Pharmacy Benefit Manager (PBM) segment in the US, a critical channel that manages prescription drug benefits for over 275 million Americans. In the first half of the year, Wanda signed a new contract with Sav-Rx, a leading US PBM serving a network of more than 65,000 pharmacies nationwide. This agreement has the potential to deliver multi-million-pound annual recurring revenue, and onboarding is already under way. Additional PBM relationships are also in development.
The company’s provider business is also performing well, with four new sites now running Medicare RTM, RPM, and CMM programmes with Wanda across areas including sleep apnoea, pain management and chronic disease management.
In addition, Wanda has begun onboarding a group of assisted living facilities across California, marking a new use case for the company. The anticipated patient ramp-up from this cohort is expected to deliver £233,000 in recurring revenue by the end of 2025.
